Clinical Trials

Multiple Myeloma

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

BreastGastrointestinalGenitourinaryThoracic

298 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

129 enrolled 16 charts

Hodgkin Disease

NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

35 enrolled 8 charts

Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00503451 2020-12-19

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

14 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT00532389 2020-12-19

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

62 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00532675 2020-12-19

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

46 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00535951 2020-12-19

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

18 enrolled

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mesothelioma

NCT00570284 2020-12-19

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

36 enrolled

Tumor-Agnostic

Neoplasms

NCT00663832 2020-12-19

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

44 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00739414 2020-12-19

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

14 enrolled

Tumor-Agnostic

Neoplasms

NCT00788931 2020-12-19

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

15 enrolled

Breast

Breast Neoplasms

NCT00997399 2020-12-19

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

37 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01007968 2020-12-19

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

25 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Other hematologic neoplasm

46 enrolled

Chromosome Aberrations, Leukemia, Myeloid, Acute

NCT01613976 2020-12-19

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

MyeloidOther hematologic neoplasm

10 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00946647 2020-08-04

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Phase 1/2 Completed

113 enrolled 21 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01802879 2019-12-06

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Other hematologic neoplasm

9 enrolled 8 charts

Hematologic Neoplasms

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT01083602 2017-12-21

MACS1271

55 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT00880269 2017-02-23

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Other hematologic neoplasm

59 enrolled 7 charts

Leukemia, Leukemia, Myeloid, Acute

NCT01034163 2016-07-07

PATH

Phase 3 Completed

41 enrolled 7 charts

Hodgkin Disease

NCT00743288 2014-05-08

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Phase 1/2 Completed

40 enrolled 10 charts

Multiple Myeloma

NCT00412997 2012-11-27

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

14 enrolled

DermatologicLymphoid

Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00472368 2012-05-01

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

4 enrolled